Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03159403
Recruitment Status : Completed
First Posted : May 18, 2017
Last Update Posted : March 12, 2018
Sponsor:
Information provided by (Responsible Party):
Melinta Therapeutics, Inc.

Brief Summary:
This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.

Condition or disease Intervention/treatment
Gram-Positive Bacterial Infections Drug: Oritavancin

Layout table for study information
Study Type : Observational
Actual Enrollment : 325 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Actual Study Start Date : April 12, 2017
Actual Primary Completion Date : February 15, 2018
Actual Study Completion Date : March 8, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Oritavancin

Group/Cohort Intervention/treatment
Oritavancin
Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
Drug: Oritavancin
This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Other Name: Orbactiv®




Primary Outcome Measures :
  1. Types Of Primary Infections Being Treated With Oritavancin [ Time Frame: Day 1 ]
    The Types Of Primary Infections refers to whether the primary infection was skin or skin structure or other systemic infection (for example, bacteremia, prosthetic joint infection, osteomyelitis).

  2. Classification Of Primary Infections Being Treated With Oritavancin [ Time Frame: Day 1 ]
    The classification of primary infection refers to whether a skin or skin structure infection was cellulitis, abscess, wound, or other.

  3. Proportion Of Participants With Positive Cultures For Gram Positive, Gram Negative, And Anaerobic Pathogens From The Infected Site [ Time Frame: Up to 30 days after oritavancin IV infusion ]
    All microbiology results during the infection event will be reported. Microbiology results will be noted only for the infection site for which oritavancin (in addition to other agents) is administered or other site related to the primary infection in case of multiple infections. An adverse event was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.

  4. Duration Of Treatment With Oritavancin [ Time Frame: Day 1 through end of oritavancin IV infusion ]
    The number of days of treatment with oritavancin will be presented.

  5. Proportion Of Participants With A Clinical Outcome Of Cure, Improved, or Failure [ Time Frame: Up to 30 days after oritavancin IV infusion ]

    Clinical assessments will be based on participant records between end of infusion to 30 days following the last dose of Oritavancin. Clinical categories for assessment include:

    • Cure - Clinical signs and symptoms are resolved, and no additional antibiotic therapy is necessary for the treatment of the infection
    • Improved - Partial resolution of clinical signs and symptoms, and no additional antibiotic therapy is necessary for the treatment of the infection
    • Failure - Inadequate resolution, or new or worsening clinical signs and symptoms, such that additional antibiotic therapy is necessary for treatment of the infection
    • Non-evaluable - Unable to determine response because the participant record did not contain the necessary information to determine cure, improvement, or failure

  6. Proportion Of Participants With A Microbiologic Eradication Or Microbiologic Persistence [ Time Frame: Up to 30 days after oritavancin IV infusion ]

    Microbiological assessments will be based on participant records between end of infusion to 30 days following the last dose of oritavancin. Microbiological categories will include only gram positive pathogens believed to be related to the infection process and are defined as:

    • Microbiologic eradication (the baseline gram positive pathogen has been eradicated)
    • Microbiologic persistence (the baseline gram positive pathogen persists)
    • Culture drawn post-oritavancin therapy, but no information regarding microbiologic culture results
    • No culture collected following the last dose of oritavancin
    • No information available

  7. Use Of Concomitant Antibiotics With Oritavancin [ Time Frame: Day 1 through end of oritavancin IV infusion ]
    Concomitant antibiotics include those used between the first and last dose of oritavancin. The number of participants and the type of antibiotic taken will be presented.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants in real world settings (which include infusion centers, clinics, emergency departments, and observation and inpatient hospital beds), who received at least one dose of oritavancin.
Criteria

Inclusion Criteria:

  • The participant was treated with at least one dose of oritavancin for a suspected or confirmed gram positive infection, as monotherapy or part of a broader regimen.
  • At least 60 days has elapsed since the participant received the last dose of oritavancin therapy (prior to data entry into the electronic Case Report Form).

Exclusion Criteria:

  • The participant received oritavancin as a part of a controlled clinical trial.
  • The participant received oritavancin as a part of a Medicines Company-sponsored single or multi-centered pharmacoeconomic outcomes study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03159403


  Show 21 Study Locations
Sponsors and Collaborators
Melinta Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Information Global Health Science Center

Study Data/Documents: Package Insert  This link exits the ClinicalTrials.gov site
Identifier: ORBACTIV® (oritavancin)
ORBACTIV® (oritavancin). United States Prescribing Information. The Medicines Company; Parsippany, New Jersey. October 2016

Layout table for additonal information
Responsible Party: Melinta Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03159403     History of Changes
Other Study ID Numbers: MDCO-ORI-15-05
First Posted: May 18, 2017    Key Record Dates
Last Update Posted: March 12, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Bacterial Infections
Gram-Positive Bacterial Infections
Oritavancin
Anti-Bacterial Agents
Anti-Infective Agents